Last reviewed · How we verify
NCT05156086: CoVaKT
Safety and Effectiveness of COVID-19 Vaccine in Kidney Transplant Recipients
trial testing COVID-19 vaccine, booster in COVID-19 Vaccination in 1,000 participants. Status unknown.
1 August 2022
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 16 November 2021 |
| Primary completion | 1 August 2022 |
| Estimated completion | 8 November 2022 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- COVID-19 vaccine, booster — full drug profile →
Conditions studied
- COVID-19 Vaccination — all drugs for COVID-19 Vaccination →
- Renal Transplant — all drugs for Renal Transplant →
Sponsor
Seoul National University Hospital
Who can join
12 and older, any sex, with COVID-19 Vaccination or Renal Transplant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The current study is a noninterventional prospective study examining the efficacy of additional dosage of the coronavirus disease 2019 (COVID-19) vaccine in kidney transplant recipients (KTRs).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients.
Han A, Min S, Jo EA, Lee H, et al · · 2024 · cited 5× · PMID 37665287 · DOI 10.3343/alm.2024.44.1.64
Verify or expand the search:
- PubMed search for NCT05156086
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Vaccination
Currently open trials in the same condition.
- NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
- NCT06613984 — Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) · active not recruiting
- NCT06156254 — Community Care Intervention to Decrease COVID-19 Vaccination Inequities · NA · recruiting
- NCT04967807 — Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study) · NA · active not recruiting
- NCT04980560 — Gut Microbiota Profile and Its Impact on Immunity Status in COVID-19 Vaccinated Cohorts · active not recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05156086 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 15 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05156086.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing